AUPH.US | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare
Sales Analysis AUPH
For the financial year Mar 31,23, Aurinia Pharmaceuticals sales have fallen by 17.07% from last year's $41.49 million to $34.41 million this year. This marks a continuous decline for the past 5 years, with a 36.88% drop from 2 years ago 's $54.52 million. We predict Aurinia Pharmaceuticals sales to go down 9.0% to around $31.32 million during the next 12 months. The share price of Aurinia Pharmaceuticals has a positive sensitivity to increases to sales with forecast sales alone decreasing the share price by 0.4%.
Aurinia Pharmaceuticals currently has 300 employees and with sales of $34.41 million this equates to sales of $114.7 thousand per employee.
For Mar 31,23 Cost of goods sold has fallen by 73.06% from last year's $1563.0 thousand to $421.0 thousand this year. This marks a continuous decline for the past 5 years, with a 93.78% drop from 2 years ago 's $6.77 million. This cost represented 1.22% of overall sales down from 3.77% last year and is expected to rise to 1.48% next year. We predict Cost of goods sold to move up 9.8% to around $462.16 thousand during the next 12 months.
Selling General and Administrative expenses were up 6.46% from $47.08 million last year to $50.12 million this year and we expect SGA to move down 10.0% to around $45.12 million during the next 12 months.
This meant gross income was $33.99 million making a gross profit margin of 98.78% of sales, which we expect to be 92.57% next year. The share price of Aurinia Pharmaceuticals has a positive sensitivity to increases to gross profit margin.
With 300 employees, the gross income is $113.29 thousand per employee.
EBIT was -88.06% of sales and have fallen -151.06% from last year to -$30.3 million and we expect EBIT to be -$27.68 million next year.
Pre-tax income was -74.89% of sales and for this fiscal year were down -112.38% from the previous year, totaling -$25.77 million and we expect it to be -$25.31 million next year. Aurinia Pharmaceuticals paid $436.0 thousand tax. Its effective tax rate was -1.69% from 5.29% last year and estimated as -0.5% next year.
Including discontinued income, after tax income was -76.16% of sales and in this year, were down -128.04% from -$11.49 million last year to -$26.21 million and we expect it to be -$25.81 million next year. Return on Equity rose 128.7% from -0.01 last year to -0.02 and we expect it to be -25.81 million next year.